Antibiotic resistance: A growing crisis
Multi-drug resistant infections have reached crisis proportions. This year more than 2 million patients will contract one of these infections in the US, resulting in high morbidity rates, extended hospital stays, and tens of thousands of patient deaths. We are on the brink of the post-antibiotic era; a minor injury or routine surgery now has the potential to result in an untreatable infection. Novel antibiotics are desperately needed. Based on recent projections by the Pew Trusts, resistant bacterial infections will be responsible for more than 10 million deaths by 2050 if current trends continue.
Octagon Therapeutics has discovered a metabolic pathway that contributes to bacterial pathogenicity. This pathway has formed the basis for a differentiated approach to antibiotic discovery. Compounds identified with this technology are inhibitors of bacterial virulence and potent antimicrobials. Octagon now has a pipeline of promising medicines to treat highly resistant bacterial pathogens including those in the "ESKAPE" group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).
Octagon's lead program, OTG005, is highly effective against Pseudomonas and Acinetobacter infections in animal models, and has been previously shown to be safe in humans. These bacterial pathogens have been highlighted by the World Health Organization as among the most dangerous and present a critical unmet medical need. Octagon is pursuing the rapid development of this new class of antibiotics.
contact investors at octagontherapeutics.com for more information